DK1098635T3 - Enterisk coatet farmaceutisk tablet indeholdende didanosin - Google Patents

Enterisk coatet farmaceutisk tablet indeholdende didanosin

Info

Publication number
DK1098635T3
DK1098635T3 DK98940790T DK98940790T DK1098635T3 DK 1098635 T3 DK1098635 T3 DK 1098635T3 DK 98940790 T DK98940790 T DK 98940790T DK 98940790 T DK98940790 T DK 98940790T DK 1098635 T3 DK1098635 T3 DK 1098635T3
Authority
DK
Denmark
Prior art keywords
didanosine
enteric coated
tablet containing
pharmaceutical tablet
coated pharmaceutical
Prior art date
Application number
DK98940790T
Other languages
Danish (da)
English (en)
Inventor
Ismat Ullah
Gary J Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1098635T3 publication Critical patent/DK1098635T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98940790T 1998-07-17 1998-08-06 Enterisk coatet farmaceutisk tablet indeholdende didanosin DK1098635T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11841898A 1998-07-17 1998-07-17

Publications (1)

Publication Number Publication Date
DK1098635T3 true DK1098635T3 (da) 2004-08-09

Family

ID=22378467

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98940790T DK1098635T3 (da) 1998-07-17 1998-08-06 Enterisk coatet farmaceutisk tablet indeholdende didanosin

Country Status (35)

Country Link
US (2) US6331316B1 (cs)
EP (1) EP1098635B1 (cs)
JP (1) JP2002520350A (cs)
KR (1) KR100535954B1 (cs)
CN (1) CN1195499C (cs)
AR (1) AR019934A1 (cs)
AT (1) ATE268165T1 (cs)
AU (1) AU750388B2 (cs)
BG (1) BG65443B1 (cs)
BR (1) BR9815948A (cs)
CA (1) CA2337885C (cs)
CO (1) CO5090840A1 (cs)
CZ (1) CZ301557B6 (cs)
DE (1) DE69824319T2 (cs)
DK (1) DK1098635T3 (cs)
EE (1) EE05021B1 (cs)
EG (1) EG23944A (cs)
ES (1) ES2221188T3 (cs)
GE (1) GEP20032912B (cs)
HU (1) HU226492B1 (cs)
ID (1) ID27019A (cs)
IL (1) IL139701A0 (cs)
LT (1) LT4844B (cs)
LV (1) LV12638B (cs)
NO (1) NO330554B1 (cs)
NZ (1) NZ508298A (cs)
PL (1) PL195587B1 (cs)
PT (1) PT1098635E (cs)
RO (1) RO121082B1 (cs)
RU (1) RU2201217C2 (cs)
SK (1) SK285152B6 (cs)
TR (1) TR200003577T2 (cs)
UA (1) UA73092C2 (cs)
WO (1) WO2000003696A1 (cs)
ZA (1) ZA993446B (cs)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6756811B2 (en) * 2000-03-10 2004-06-29 Easic Corporation Customizable and programmable cell array
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
MXPA03007337A (es) 2001-02-15 2005-03-07 King Pharmaceuticals Inc Composicion farmaceutica y de hormona tiroidea estabilizada y metodo de preparacion de la misma.
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
JP2005511515A (ja) 2001-09-28 2005-04-28 マクニール−ピーピーシー・インコーポレイテッド 互いに異なる形状の内側コア及び外側シェルを有する投薬形態
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
AU2003201735B2 (en) * 2002-01-11 2008-11-13 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2003072089A1 (en) * 2002-02-21 2003-09-04 Biovail Laboratories Inc. Controlled release dosage forms
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1551356A2 (en) * 2002-09-03 2005-07-13 Biovail Laboratories Incorporated Pravastatin pharmaceutical formulations and methods of their use
JP2006503045A (ja) * 2002-09-16 2006-01-26 ワイエス ポリペプチド治療薬剤の経口投与のための遅延放出処方物と同薬剤の使用方法
PT2772250T (pt) * 2002-10-01 2017-01-02 Banner Life Sciences Llc Composição entérica para o fabrico de uma parede de cápsula mole
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
AU2004311849B2 (en) * 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
JP2007522135A (ja) 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
US20100183714A1 (en) * 2004-03-26 2010-07-22 Lek Pharmaceuticals D.D. Gastroresistant pharmaceutical dosage form comprising n-(2-(2- phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
RU2276974C2 (ru) * 2004-07-01 2006-05-27 Некоммерческое партнерство Научно-технический центр "Лекарства и биотехнология" (НТЦ "Лекбиотех") Лекарственное средство "гастропек" для улучшения процессов пищеварения и способ его применения
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
ATE397442T1 (de) * 2004-11-18 2008-06-15 Bristol Myers Squibb Co Magensaftresistent beschichtetes pellet mit ixabepilon
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
MX2007007836A (es) * 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CN100398122C (zh) * 2005-01-28 2008-07-02 北京北大药业有限公司 一种治疗颈、腰椎病中药的肠溶包衣组合物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DK1916995T4 (da) 2005-07-29 2022-10-03 Stichting Groningen Centre For Drug Res Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf
AU2006275679B2 (en) * 2005-07-29 2012-04-12 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
KR20080047375A (ko) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
SI2535044T1 (sl) 2006-01-27 2020-06-30 The Regents Of The University Of California Cisteamin bitartrat in cistamin z enterično oblogo
KR102144926B1 (ko) 2006-03-17 2020-08-14 더 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
WO2008015686A1 (en) * 2006-08-01 2008-02-07 Hetero Drugs Limited Stable multiparticulate formulations of didanosine
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
AU2008304200B2 (en) 2007-09-26 2013-12-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
TWI592159B (zh) * 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
EP2636404B1 (en) * 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
PT2278975T (pt) 2008-05-07 2016-11-08 Cardioxyl Pharmaceuticals Inc Novos compostos de nitroso como dadores de nitroxilo e métodos de utilização dos mesmos
US20090317466A1 (en) * 2008-06-18 2009-12-24 Franco Lori Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
EP2303018B1 (en) 2008-06-19 2015-10-14 Xcovery Holding Company LLC Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
ES2586439T3 (es) * 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
WO2010042163A2 (en) 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
ES2600960T3 (es) 2009-02-24 2017-02-13 Ritter Pharmaceuticals, Inc. Formulaciones prebióticas y procedimientos de uso
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
PT2407166E (pt) * 2009-03-13 2013-11-25 Toyama Chemical Co Ltd Comprimido e pó granulado que contêm 6-fluoro-3-hidroxi-2-pirazinacarboxamida
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
AU2010328230B2 (en) * 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
WO2011137249A1 (en) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
PL2625176T3 (pl) 2010-10-08 2017-08-31 Xcovery Holding Company Llc Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
WO2013049731A1 (en) * 2011-09-30 2013-04-04 Stomavite Llc A supplement for ostomy patients
US9181213B2 (en) 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
CN102526746B (zh) * 2012-02-04 2013-09-18 安徽山河药用辅料股份有限公司 肠溶型水分散体包衣材料的制备方法
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
SMT201900575T1 (it) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals Inc Donatori di nitrossile con indice terapeutico migliorato
BR112015025460B1 (pt) 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN120695169A (zh) 2013-12-20 2025-09-26 博德研究所 使用新抗原疫苗的联合疗法
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US20170216328A1 (en) 2014-04-04 2017-08-03 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2015195989A1 (en) 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
CN107108560B (zh) 2014-12-23 2020-11-10 塞里考股份有限公司 化合物、组合物及其方法
RU2668499C2 (ru) * 2015-03-12 2018-10-01 Закрытое Акционерное Общество "Фармфирма "Сотекс" Фармацевтическая композиция в форме таблеток, покрытых кишечнорастворимой оболочкой, и способ ее получения
HK1252267A1 (zh) 2015-05-20 2019-05-24 The Broad Institute Inc. 共有的新抗原
EP4008321A1 (en) 2015-06-09 2022-06-08 Ocuphire Pharma, Inc. Fluorocyclopentenylcytosine for treating tumour
MX2018002193A (es) 2015-09-04 2018-08-01 Rexahn Pharmaceuticals Inc Metodo de uso de quinoxalinilo-piperazinamida.
CN115252650A (zh) 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
WO2017087532A1 (en) 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
ES2875320T3 (es) 2016-05-04 2021-11-10 Den Driessche Herman Van Formulación de simmondsina
USRE49834E1 (en) 2016-10-03 2024-02-13 Hangzhou Highlightll Pharmaceutical Co., Ltd. Jak1 selective inhibitors and uses thereof
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
BR112020022294A2 (pt) 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
PT3891267T (pt) 2018-11-05 2024-07-04 Marvelbiome Inc Composições microbianas que compreendem elagitanina e métodos de utilização
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020212822A1 (en) * 2019-04-17 2020-10-22 Amruth Gowda Doddaveerappa Multi-component pharmaceutical single dosage forms and process employed thereof
WO2020215037A1 (en) 2019-04-18 2020-10-22 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
CN110882228A (zh) * 2019-11-29 2020-03-17 南京禾瀚医药科技有限公司 一种伊匹乌肽肠溶制剂
ES2975442T3 (es) * 2019-12-11 2024-07-05 Evonik Operations Gmbh Forma farmacéutica para su uso en el tratamiento o la prevención de una enfermedad
KR20230029673A (ko) 2020-05-26 2023-03-03 디오니스 테라퓨틱스, 아이엔씨. 핵산 인공 미니-프로테옴 라이브러리
WO2021248093A1 (en) 2020-06-05 2021-12-09 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
AU2021410726A1 (en) 2020-12-22 2023-07-13 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
WO2023016321A1 (zh) 2021-08-10 2023-02-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024228542A1 (ko) * 2023-05-04 2024-11-07 풍림무약주식회사 장용성 코팅용 조성물 및 이를 이용한 정제의 제조 방법
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4432996A (en) 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8512330D0 (en) 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
WO1987001284A1 (en) 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
JP3025528B2 (ja) * 1989-11-24 2000-03-27 ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング パンクレアチン製剤
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
EP0563294A1 (en) * 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyamine drug-resin complexes
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
DE69331906T2 (de) 1992-08-05 2002-12-19 F.H. Faulding & Co. Ltd., Underdale Granulierte pharmazeutische zusammensetzung
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
WO2000003696A1 (en) 2000-01-27
US6569457B2 (en) 2003-05-27
EG23944A (en) 2008-01-22
IL139701A0 (en) 2002-02-10
EP1098635B1 (en) 2004-06-02
ID27019A (id) 2001-02-22
HUP0102659A2 (hu) 2002-03-28
CN1338925A (zh) 2002-03-06
EP1098635A1 (en) 2001-05-16
AU8898398A (en) 2000-02-07
EP1098635A4 (en) 2002-01-16
UA73092C2 (uk) 2005-06-15
KR100535954B1 (ko) 2005-12-12
CZ2001215A3 (cs) 2001-10-17
AU750388B2 (en) 2002-07-18
NO20010260D0 (no) 2001-01-16
CN1195499C (zh) 2005-04-06
ES2221188T3 (es) 2004-12-16
ATE268165T1 (de) 2004-06-15
NO330554B1 (no) 2011-05-16
LV12638A (lv) 2001-04-20
BR9815948A (pt) 2001-02-28
PL195587B1 (pl) 2007-10-31
LT2001003A (en) 2001-06-25
SK285152B6 (sk) 2006-07-07
PT1098635E (pt) 2004-09-30
RO121082B1 (ro) 2006-12-29
US6331316B1 (en) 2001-12-18
KR20010070981A (ko) 2001-07-28
BG65443B1 (bg) 2008-08-29
NZ508298A (en) 2003-11-28
HU226492B1 (en) 2009-03-02
JP2002520350A (ja) 2002-07-09
CZ301557B6 (cs) 2010-04-14
US20020051818A1 (en) 2002-05-02
DE69824319T2 (de) 2005-08-04
GEP20032912B (en) 2003-03-25
LV12638B (lv) 2001-09-20
DE69824319D1 (de) 2004-07-08
AR019934A1 (es) 2002-03-27
CA2337885C (en) 2008-01-08
SK18832000A3 (sk) 2002-01-07
BG105203A (bg) 2001-09-28
HUP0102659A3 (en) 2002-12-28
ZA993446B (en) 2000-11-20
RU2201217C2 (ru) 2003-03-27
LT4844B (lt) 2001-09-25
CA2337885A1 (en) 2000-01-27
NO20010260L (no) 2001-03-07
EE05021B1 (et) 2008-06-16
CO5090840A1 (es) 2001-10-30
EE200100033A (et) 2002-06-17
TR200003577T2 (tr) 2001-06-21
PL345774A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
DK1098635T3 (da) Enterisk coatet farmaceutisk tablet indeholdende didanosin
LU90245B1 (fr) Pilules de fluox-tine ent-riques
EE9900540A (et) Omeprasooli ravimvorm
NO20001776D0 (no) Medikamenter
DK0966287T3 (da) Oxacarbazepinfilmovertrukne tabletter
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
DE69820407D1 (de) Blisterpackung
IS5869A (is) Hraðlosandi tafla
ID23735A (id) Tablet trovafloksasin mesilat
DK1466615T3 (da) Farmaceutisk præparat
MA24417A1 (fr) Comprime detrgent enrobe
DK1017392T3 (da) Lægemiddel
ATE309838T1 (de) Pharmazeutisches implantat
ATE237529T1 (de) Tablettenspender
DK1069896T3 (da) Lægemidler indeholdende carvedilol
NO20016430L (no) Farmasöytisk kompleks
GB0000482D0 (en) Enteric coated pharmaceutical formulation
UA2855S (uk) Таблетка фармацевтична
GB9814214D0 (en) Enteric coated pharmaceutical formulation
KR970008018U (ko) 장제용 위패
FR2772264B1 (fr) Pilulier
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat
UA1246S (uk) Таблетка фармацевтична
CA84666S (en) Pharmaceutical tablet
CA83558S (en) Pharmaceutical tablet